Team |
Kathryn Woodburn, PhD
Kathryn Woodburn, PhD

Kathryn Woodburn, PhD

Senior VP

Preclinical Development

Kathryn oversees the timely preclinical development of drug candidates from discovery to the clinic and subsequent regulatory approval.

Prior to joining Life Edit, Kathryn was an independent consultant and had worked at Avalanche Biotechnologies/Adverum, Affymax, AP Pharma and Pharmacyclics. She has overseen preclinical development for gene therapy, oncology, cardiology, ophthalmology, pain management, anti-infectives, hematology and tissue protection programs.

Kathryn received her PhD in Chemistry and Biochemistry from La Trobe University in Australia with thesis titled ‘‘Synthesis and biological evaluation of porphyrins for use in photodynamic therapy of brain tumors,” after which she completed postdoctoral studies at the University of Toledo and Wayne State University. She has generated eight patents and over sixty manuscripts.

Connect with

Visionary science, driven by visionary values.

Our Mission

To rewrite the future by curing disease, making any edit, anywhere.

Our Vision

To pave the way to faster, safer, gene editing therapeutics that cure disease and improve patient lives.

Our Values

We’re guided by curiosity, rigor, and integrity. We believe in discovery and unlimited potential. We care about science and the lives of patients.